

Index

Note: Page numbers followed by “f” indicate figures and those followed by “t” indicate tables.

a

AA, *see* arachadonic acid
 abaxial/mid-body/central meniscal release, 303
 Absolute Risk Increase (ARI), 318
 Absolute Risk Reduction (ARR), 317
 accelerometers, 319
 ACL, *see* anterior cruciate ligament
 adult mesenchymal stromal cells, 336
 aLDFA, *see* anatomic lateral distal femoral angle
 allografts
 DDFT, 210
 in intra-articular stabilization, 204–206, 205f–206f
 amantadine, 335
 analgesics, 335–336
 anatomic lateral distal femoral angle (aLDFA),
 262–263, 264f
 angular limb deformities, 235–236
 anterior cruciate ligament (ACL), 202
 rupture repair, 62, 202
 anti-collagen type I and II antibodies, 89–90
 anti-nerve growth factor antibody, 336
 arachadonic acid (AA), 337
 ARI, *see* Absolute Risk Increase
 ARR, *see* Absolute Risk Reduction
 arthroscopic appearance of stifle synovium in dogs,
 97f
 arthroscopic-assisted arthrotomy, 177–180
 arthroscopic follow-up examination, stifle, 279–289
 after extracapsular stabilization, 287–288, 287f–288f
 after intra-articular stabilization, 288–289, 288f
 after tibial plateau leveling osteotomy (TPLO),
 280–287, 280f–286f
 arthroscopy, history, 171

aseptic loosening, 368–369, 369f
 aspirin, 335
 aspirin triggered lipoxins (ATLs), 335
 ASUs, *see* avocado and soybean oil unsaponifiables
 ATLs, *see* aspirin triggered lipoxins
 autografts, in intra-articular stabilization, 203–204
 avocado and soybean oil unsaponifiables (ASUs),
 338

b

bilateral lameness, 115, 116f
 biomaterials, 372
 biomechanics of stifle, 227–231, 228f–231f
 BioMedtrix total knee replacement (TKR) implant,
 364–365, 364f
 biplanar fluoroscopy, 272
 bone
 screws, in tibial plateau leveling osteotomy, 219,
 221
 botulinum toxin A, 336
 braces, 264

c

Canine Brief Pain Inventory (CBPI), 318
 canine and human cruciate ligament rupture, 61–62
 canine stifle joint disorders, 135
 cartilage damage, 97
 cartilage oligomeric matrix protein (COMP), 360
 caudal cruciate ligament (CaCL), 40
 CBPI, *see* Canine Brief Pain Inventory
 CCWO, *see* closing cranial wedge osteotomy
 chondroitin sulfate, 337–338
 client-specific outcome measures (CSOM), 318

- clinical outcomes, after surgical treatment of cruciate ligament rupture (CR), 313
 - affecting factors, 315
 - early postoperative, 313–314
 - mid- and long-term, 313f–314f, 314
- clinical trial design
 - blinding and outcome assessment, 360
 - control group definition, 357
 - intervention versus control groups, assignment to, 357–358, 360
 - overview, 357
 - placebo effects, 359t, 360
 - study population definition, 357
- closing cranial wedge osteotomy (CCWO), 221, 243, 246f, 252, 254, 254f, 256–259, 261, 272, 275
 - complications, 247
 - implant selection, 246–247
 - outcome for, 247–248
 - patient selection, 244–245
 - technique research, 243–244
 - intraoperative, 244
 - planning, 244, 245f
- Clostridium botulinum*, 336
- collagen turnover, 65
- collagen type I and II, 89
 - relevance of antibodies to collagen types I and II, 90–91
- COMP, *see* cartilage oligomeric matrix protein
- comparative value of the canine model, 62
- complete cruciate ligament rupture, dogs with, 292–293, 292f–293f
- concurrent meniscal pathology, 295
 - algorithm for decision-making of surgical treatment, 299f
 - diagnosis of, 295–296
 - resection procedures used in dogs, 297t
 - treatment of, 296–299, 298f
 - types, 295, 296f
- contralateral cranial cruciate ligament (CrCL), 89
- cortical bone, 161
- COX, *see* cyclooxygenase
- cranial cruciate ligament (CrCL)
 - clinical presentation, 123–124
 - cranial joint space, 135
 - cranial traction, 172
 - deficiency, 39
 - deficient stifle, 35, 41–43, 189
 - diagnosis of, 120
 - fibers, 121
 - partial rupture of, 119–121
 - rupture of, 123
 - sectioning of, 120t
 - treatment, 124
- cranial cruciate ligament (CrCL)-deficient minipig, 373
- cranial cruciate ligament (CrCL) rupture in dogs,
 - intra-articular repair for
 - biology of, 208–210, 209f
 - deficient stifle, 264–265, 265f
 - treatment by tibial osteotomies, 271–276, 273f–276f
 - fixation, 207–208
 - future developments, 210, 210f–211f
 - graft selection
 - allografts, 204–206, 205f–206f
 - autografts, 203–204
 - prosthetics, 206–207
 - historical use, 202–203
 - ligament debridement for, 291–294
- cranial cruciate ligament (CrCL) tensile strength, 101
- cranial tibial thrust, 221
- cruciate ligament
 - functional anatomy, 9
 - innervation, 8–9
 - macroanatomy, 3–5
 - microanatomy, 5–6
 - morphology, 3–5
 - synovial envelope, 68
 - vascular supply, 6–8
- cruciate ligament matrix metabolism
 - in human beings and other species, 65
 - in ruptured canine cruciate ligaments, 68–69
- cruciate ligament rupture (CR), 201
 - clinical outcomes after surgical treatment of, 313
 - affecting factors, 315
 - early postoperative, 313–314
 - mid- and long-term, 313f–314f, 314
 - clinical signs of, 116–118
 - epidemiology of, 109–112
 - bilateral, 111–112
 - genetics, 112
 - genetics of, 57–61
 - candidate gene analysis, 58–59
 - complex trait genetics, 58
 - genome-wide association, 59–61
 - heritability, 57
 - history, 115–116
 - with meniscal pathology, 295–299
 - morphological risk factors for, 73–77
 - distal femoral intercondylar notch, 73
 - fabella, 77
 - patella/quadriceps mechanism and Q-angle, 77
 - tibia, 76–77
 - obesity, 110
 - and osteoarthritis, 307
 - with patellar luxation
 - management of, 264–268, 265f–267f
 - pathophysiology of, 261
 - patient evaluation, 262–264, 263f–265f
 - pathology of, 47
 - adaptation and repair, 51–54
 - histologic features of, 48
 - histopathology of canine, 49–51
 - pelvic limb lameness in dogs and, 279
 - rehabilitation for dogs with, 343
 - changes in posture, prevention and recovery from, 345, 347f

- considerations, 347t
 - goals of, 343–347
 - limb use, promotion of, 344, 345f
 - management protocols, 349–351, 350f
 - mechanical complications after surgery,
 - prevention from, 345, 347
 - motor control, prevention and recovery from
 - loss of, 345, 345f–346f
 - muscle mass, prevention and recovery from loss
 - of, 345, 345f–346f
 - pain relief, 343–344
 - postoperative edema, elimination of, 344
 - proactive, 349–350
 - retroactive, 349–350
 - scientific evidence for, 349
 - stifle joint motion, maintaining/recovering, 344, 344f
 - strategies, 347–349, 347t, 348f
 - remodeling and repair, 23–28
 - healing potential of graft interface tissue, 25–28
 - healing potential of reconstructed cranial cruciate ligament (CrCL) graft, 24–25
 - healing potential of ruptured cranial cruciate ligament (CrCL), 22–23
 - healing potential of surgically repaired cranial cruciate ligament (CrCL), 24
 - risk factors for, 111t
 - risk prediction of, 165–166
 - magnetic resonance imaging, 166
 - radiography, 165–166
 - subtle effusion, 116
 - surgical treatment outcomes, 201–202
 - CSOM, *see* client-specific outcome measures
 - cyclooxygenase (COX), 334–335, 337, 343
- d**
- DDFT, *see* deep digital flexor tendon
 - debridement, for cranial cruciate ligament (CrCL)
 - rupture, 291–292
 - complete, 292–293, 292f–293f
 - partial, 293–294, 293f
 - decellularization, 205–206
 - deep digital flexor tendon (DDFT), 208, 210
 - deep intra-articular structures, 136
 - distribution of proteoglycan, 32
 - doxycycline, 380
- e**
- edema, 344
 - endothelial (eNOS) isoforms of nitric oxide synthase, 81
 - eTPA, *see* excessive tibial plateau angle
 - excessive tibial plateau angle (eTPA), 221, 233, 235, 253–259
 - closing cranial wedge osteotomy (CCWO) for, 253, 254f
 - outcome, 259
 - preoperative planning for, 253, 254f–257f, 255–258
 - surgical technique for, 258–259
 - tibial plateau leveling osteotomy (TPLO) for, 253, 254f
 - extracapsular stabilization (ES) technique, 189, 196
 - biological extracapsular stabilization, 190
 - case selection, 189
 - general care after surgery, 190
 - isometry, 194
 - surgical approach, 189–190
 - suture material, 193
 - extracellular matrix (ECM), 65
 - biomaterial, 372
 - proteins, 372
- f**
- femoral condyles, 136
 - femoral and tibial attachment
 - clinical outcome, 196–197
 - methods of securing suture, 194–195
 - stifle position while securing suture, 195–196
 - fibular fractures, after tibial plateau leveling osteotomy (TPLO), 222, 222f
 - first-generation tibial tuberosity advancement (TTA)
 - complications, 238–239
 - implants and techniques, 232
 - outcome, 238–239
 - flexion–extension motion, 39
 - force platform gait analysis, 320
 - fractures, as a complication of tibial plateau leveling osteotomy (TPLO), 222, 222f
- g**
- GABA, *see* gamma-aminobutyric acid
 - gabapentin, 335–336
 - gamma-aminobutyric acid (GABA), 335–336
 - Gelpi retractor, 172–173
 - glucocorticoids, 381
 - glucosamine, 337–338
 - grafts
 - allografts, 204–206, 205f–206f
 - autografts, 203–204
 - fixation, 207–208
 - intra-articular, use in restoration of joint stability, 207–210
 - non-destructive assessment of, 373, 373f
 - non-invasive assessment of, 373, 373f
 - patella tendon, 203–204
 - gram-positive aerobic bacteria, 328
- h**
- HA, *see* hyaluronic acid
 - health measurement instruments
 - reliability testing, 356–357
 - stepwise development of, 356–357, 356f, 358t
 - validation of, 357
 - hoop tension theory, schematic depiction of, 36f
 - hyaluronic acid (HA), 337

i

implant
 closing cranial wedge osteotomy, 244–246
 selection, in tibial plateau leveling osteotomy (TPLO), 219, 220f, 221
 tibial tuberosity advancement, 232
 inducible isoform of nitric oxide synthase (iNOS), 81
 intra-articular corticosteroids, 185
 intra-articular grafts, for restoration of joint stability, 207–210
 intra-articular repairs, 202–203
 intra-articular stabilization
 allografts, use in, 204–206
 autografts, use in, 203–204
 intra-articular ligament replacement, 204–206, 206f
 intra-articular repairs, 202–203
 prosthetics, use in, 206–207
 isometry, 194

j

jig
 for tibial plateau leveling osteotomy, 257, 257f
 use in tibial plateau leveling osteotomy, 218
 joint inflammation, 93
 joint lavage
 clinical studies, 185–186
 mechanism for relief of, 186
 joints limit motion, 155
 joint tissues
 antigen-specific immune responses, 103
 innate immune responses, 103–105

k

knee replacement in dog, total, *see* total knee replacement in dog

l

Liverpool Osteoarthritis in Dogs (LOAD), 318
 LOAD, *see* Liverpool Osteoarthritis in Dogs

m

material properties of the meniscus, 35
 matrix metalloproteinases (MMPs), 379–380
 MCL, *see* medial collateral ligament
 mechanical lateral distal femoral angle (mLDFA), 263, 264f
 mechanical medial distal tibial angle (mMDTA), 263
 mechanical medial proximal tibial angle (mMPTA), 263
 mechanoreceptors, 291–292
 medial collateral ligament (MCL), 368
 medial meniscal release, 302–303
 medial patella luxation (MPL), 250
 meniscal cells, 32
 meniscal damage, 123

meniscal injury, 295
 algorithm for decision-making of surgical treatment, 299f
 diagnosis of, 295–296
 resection procedures used in dogs, 297t
 treatment of, 296–299, 298f
 types, 295, 296f
 meniscal release, 301–302
 clinical decision-making and, 305–306
 in dogs, 299t
 and joint biomechanics and biology, 302–303, 303f–304f
 medial, 302–303
 surgical technique, 303–305, 304f
 and tibial plateau leveling osteotomy, 219
 and tibial tuberosity advancement (TTA), 238
 types of, 303
 meniscal structure, 31–36
 biomechanical and material properties, 34–35
 meniscal function, 35–36
 neurovascular anatomy, 32–34
 surgical anatomy, 31–32
 meniscal tear, 138, 139f
 menisci, extracellular matrix (ECM) of, 32
 menisco-tibial release, 303–305
 mesenchymal stem cells (MSCs), 336, 381
 mLDFA, *see* mechanical lateral distal femoral angle
 mMDTA, *see* mechanical medial distal tibial angle
 MMPs, *see* matrix metalloproteinases
 mMPTA, *see* mechanical medial proximal tibial angle
 morphology, 73
 MPL, *see* medial patella luxation
 MSCs, *see* mesenchymal stem cells
 multi-drug-resistant (MDR) bacteria, 325

n

neoplastic disorders, 146
 nerve growth factor (NGF), 336
 neuronal (nNOS) isoforms of nitric oxide synthase, 81
 NGF, *see* nerve growth factor
 nitric oxide (NO)
 in articular tissues, 82
 cranial cruciate ligament (CrCL) structure, 85–86
 influence of, 85–86
 matrix metalloproteinases (MMPs), 85–86
 overview, 84
 role of matrix metalloproteinases (MMPs), 84–85
 nitric oxide synthase (NOS), 81
 N-methyl-D-aspartate (NMDA) receptors, 335
 NNH, *see* Number Needed to Harm
 NNT, *see* Number Needed to Treat
 nonsteroidal anti-inflammatory drugs (NSAIDs), 334–335, 381
 NRS, *see* numeric rating score
 NSAIDs, *see* nonsteroidal anti-inflammatory drugs

- nucleotide-binding oligomerization domain (NOD), 103
- Number Needed to Harm (NNH), 317–318, 318t
- Number Needed to Treat (NNT), 317–318, 318t
- numeric rating score (NRS), 319
- O**
- OA, *see* osteoarthritis
- omega-3 fatty acids, 337
- orthopaedic disease, owner assessments in, 355–356
- orthopaedic surgical infections of stifle, 323
- definition, 323–324
- diagnosis, 326
- economic impact, 328
- incidence of, 324–325
- pathogens, 325–326
- prognosis of, 328
- rates, 324–325
- treatment, 326–328, 327f
- osteoarthritis (OA), 202, 307
- cranial cruciate ligament (CrCL) transection as model of, 307, 308f
- progression after stifle stabilization procedures, 308
- causes, 308–310
- comparison of methods, 310
- radiographic progression, 309t
- stifle, medical therapy for, 333–334
- adjunctive therapies, 333
- analgesics, 335–336
- biological products, 336
- care-giver placebo effect, 333–334
- chondromodulating agents, 336–337
- dietary supplements, 337–338
- goals of, 333
- NSAIDs, 334–335
- weight management, 334
- and stifle instability with cranial cruciate ligament (CrCL) rupture, 308
- over-the-top technique, 203
- owner assessments, in orthopaedic disease, 355–356
- P**
- partial cruciate ligament rupture, dogs with, 293–294, 293f
- patellar luxation
- cruciate ligament rupture with
- management of, 264–268, 265f–267f
- pathophysiology of, 261
- patient evaluation, 262–264, 263f–265f
- tibial tuberosity advancement (TTA), 236, 237f
- patellar tendon
- enlargement, after tibial plateau leveling osteotomy, 221
- insertion point, low versus high, 233, 235f
- patella tendon angle (PTA), 217, 227–229, 228f–229f, 231, 231f
- patella tendon autograft, 203–204
- pathomechanics theory of osteoarthritis, diagrammatic presentation, 43
- patient morbidity, 182–183
- patient size, tibial tuberosity advancement (TTA), 236–237, 237f
- pedometers, 319
- pivot shift, 221–222
- placebo effects, 359t, 360
- platelet-rich plasma (PRP), 336, 372
- platelets, 372
- polysulfated glycosaminoglycan (PSGAG), 336–337
- polyunsaturated fatty acids (PUFAs), 337
- postliminary tears, 301
- pressure mat gait analysis, 353
- prosthetics, use in intra-articular stabilization, 206–207
- proteoglycans, 62
- PRP, *see* platelet-rich plasma
- PSGAG, *see* polysulfated glycosaminoglycan
- PTA, *see* patella tendon angle
- PUFAs, *see* polyunsaturated fatty acids
- Q**
- questionnaires, owner, 318–319
- R**
- randomized controlled clinical trials (RCTs), 357
- RCTs, *see* randomized controlled clinical trials
- regenerative medicine, cranial cruciate ligament (CrCL) and, 371
- additional factors, 373, 375
- arthritic degeneration, 373
- cruciate ligaments, healing of, 371–372, 372f
- biomaterial, 372
- non-destructive assessment of graft properties, 373, 373f
- non-invasive assessment of graft properties, 373, 373f
- signaling, 372–373
- preclinical studies for, 375–376
- surgical treatments, comparative effectiveness of, 371
- rehabilitation for dogs with cruciate ligament rupture, 343
- changes in posture, prevention and recovery from, 345, 347f
- considerations, 347t
- goals of, 343–347
- limb use, promotion of, 344, 345f
- management protocols, 349–351, 350f
- mechanical complications after surgery, prevention from, 345, 347
- motor control, prevention and recovery from loss of, 345, 345f–346f

- rehabilitation for dogs with cruciate ligament rupture
(*Continued*)
 muscle mass, prevention and recovery from loss of,
 345, 345f–346f
 pain relief, 343–344
 postoperative edema, elimination of, 344
 proactive, 349–350
 retroactive, 349–350
 scientific evidence for, 349
 stifle joint motion, maintaining/recovering, 344,
 344f
 strategies, 347–349, 347t, 348f
 Relative Risk Reduction (RRR), 317
 reproductive status
 as risk factor for cranial cruciate ligament (CrCL)
 rupture, 109
 RRR, *see* Relative Risk Reduction
- S**
- second-generation tibial tuberosity advancement
 (TTA)
 complications with, 239–240, 239f
 implants and techniques, 232
 outcome, 239–240
 Securos tibial plateau leveling osteotomy (TPLO)
 plate, 219
 signaling, 372–373
 single-plane fluoroscopy, 272
 size of patient, and tibial tuberosity advancement,
 236–237, 237f
 Slocum tibial plateau leveling osteotomy (TPLO)
 plate, 219
 SSI, *see* surgical site infections
 stifle
 arthroscopic follow-up examination, 279–289
 after extracapsular stabilization, 287–288,
 287f–288f
 after intra-articular stabilization, 288–289, 288f
 after tibial plateau leveling osteotomy (TPLO),
 280–287, 280f–286f
 arthrotomy, 171
 arthroscopy of, 174–177
 overview, 171
 biomechanics of, 227–231, 228f–231f
 computed tomography (CT), 141–146
 features of, 143–146
 indications for, 141
 technical aspects, 142–143
 cranial cruciate ligament (CrCL)-deficient, 264–265,
 265f
 distraction, 180–181
 instability associated with, 92–98
 synovial assessment, 96
 synovitis, 94–96
 synovitis in cruciate ligament rupture, 96–98
 joint motion, maintaining/recovering, 344, 344f
 magnetic resonance imaging, 155–161
 image acquisition, 155–156
 meniscus, 156–161
 synovial structures, 156
 orthopaedic surgical infections, 323
 definition, 323–324
 diagnosis, 326
 economic impact, 328
 incidence of, 324–325
 pathogens, 325–326
 prognosis of, 328
 treatment, 326–328, 327f
 osteoarthritis, medical therapy for, 333–334
 adjunctive therapies, 333
 analgesics, 335–336
 biological products, 336
 care-giver placebo effect, 333–334
 chondromodulating agents, 336–337
 dietary supplements, 337–338
 goals of, 333
 nonsteroidal anti-inflammatory drugs (NSAIDs),
 334–335
 weight management, 334
 stabilization surgery, 271–272
 accelerometers, 319
 data reporting, 320
 force platform gait analysis, 320
 owner questionnaires and, 318–319
 pedometers, 319
 residual lameness, 320–321, 321f
 success and failure, 317–318
 veterinary examination, 319
 stress imaging of, 128–132
 measuring subluxation, 128–129
 standing radiography, 131
 stress devices, 130
 stress-magnetic resonance imaging (MRI),
 131–132
 tibial compression radiography, 129–130
 ultrasonography, abnormal, 137–140
 stress devices, 130
 surgical site infections (SSI), 323–324, 324t
 deep, 324t
 organ/space, 324t
 superficial, 324t
 synovial immune responses, in stifle synovitis,
 101–105
 synovial inflammation, 379
 synovial membrane, 93
 synovitis, 94–96
 Synthes tibial plateau leveling osteotomy (TPLO)
 plate, 219
- T**
- tartrate-resistant acid phosphatase-positive (TRAP)
 macrophages, 101, 102f

- T-cell inhibitors, 380–381
 - technical failures, tibial tuberosity advancement (TTA), 238–239
 - tetracyclines, 379–380
 - tibia fractures, after tibial plateau leveling osteotomy (TPLO), 222, 222f
 - tibial osteotomies
 - biomechanics of, 272–276, 273f–276f
 - tibial plateau angle (TPA), 217–219, 218f, 221, 243–244
 - excessive, 221, 233, 235, 236f, 253–259. *See also* excessive tibial plateau angle (eTPA)
 - measurement, 218, 218f
 - in stifle biomechanics, 272
 - tibial plateau leveling osteotomy (TPLO), 97, 136, 201, 217, 243
 - bone screws, locking/conventional, 219, 221
 - complications after, 22f, 221–223
 - for dogs with combined cruciate ligament rupture (CR) and patella luxation (PL), 266–267, 266f–267f
 - implant selection, 219, 220f, 221
 - infection rates for, 221
 - and meniscal release, 219
 - outcome after, 223
 - patient selection, 219
 - proximal tibial valgus deformity treated by, 256f
 - technique, 217–219
 - three-jig pin technique for, 257, 257f
 - tibial tuberosity
 - fracture of, as complication of tibial plateau leveling osteotomy, 222
 - in human knee joint, 227, 228f
 - tibial tuberosity advancement (TTA), 217, 227
 - case selection
 - angular and torsional limb deformities, 235–236
 - excessive tibial plateau angle (TPA), 233, 235, 236f
 - low versus high patellar tendon insertion point, 233, 235f
 - patellar luxation, 236, 237f
 - patient size, 236–237, 237f
 - for dogs with combined cruciate ligament rupture (CR) and patella luxation (PL), 268
 - first-generation
 - complications, 238–239
 - implants and techniques, 232
 - outcome, 238–239
 - implants and techniques, 231–232
 - first-generation, 232
 - second-generation, 232
 - pre-planning, 232–233, 234f–235f
 - second-generation
 - complications with, 239–240, 239f
 - implants and techniques, 232
 - outcome, 239–240
 - stifle biomechanics, 227–231, 229f–231f
 - surgery, 232–233
 - toll-like receptor (TLR), 103
 - torsional limb deformities, 235–236
 - total knee replacement (TKR) in dog
 - BioMedtrix, 364–365, 364f
 - clinical results with cemented canine, 366–367
 - complications
 - aseptic loosening, 368–369, 369f
 - infection, 367, 367f
 - joint/implant instability, 368
 - neurovascular injury, 368
 - wear of ultra-high-molecular-weight polyethylene, 368
 - contraindications for surgery, 365, 365f
 - history of, 363–364
 - indications for surgery, 365
 - laboratory testing for, 369–370
 - postoperative pain management, 366
 - surgical technique, 365–366, 366f
 - TPA, *see* tibial plateau angle
 - TPLO, *see* tibial plateau leveling osteotomy
 - tramadol, 335
 - transection of the meniscus, 35
 - transient receptor potential vanilloid 1 (TRPV1) receptor, 335
 - traumatic lesions, 146
 - triple tibial osteotomy (TTO), 248
 - complications, 250–251, 251f
 - implant selection, 249–250, 250f
 - outcome, 251
 - patient selection, 249
 - technique
 - intraoperative, 248–249, 249f
 - planning, 248
 - T-style plates, 246
 - TTA, *see* tibial tuberosity advancement
- U**
- UHMWPE, *see* ultra-high-molecular-weight polyethylene
 - ultra-high-molecular-weight polyethylene (UHMWPE), 368f
- V**
- VAS, *see* visual analog scale
 - visual analog scale (VAS), 319
- W**
- wedgie, spacer tool, 248
 - wedging phenomenon, 301–302
 - weight management, for osteoarthritis, 334

